Norges Bank Takes $49.09 Million Position in Masimo Corporation $MASI

Norges Bank bought a new position in shares of Masimo Corporation (NASDAQ:MASIFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 377,421 shares of the medical equipment provider’s stock, valued at approximately $49,087,000. Norges Bank owned approximately 0.70% of Masimo at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in MASI. Global Retirement Partners LLC bought a new position in Masimo in the fourth quarter valued at about $27,000. Rothschild Investment LLC boosted its stake in shares of Masimo by 12,950.0% during the fourth quarter. Rothschild Investment LLC now owns 261 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 259 shares in the last quarter. Torren Management LLC bought a new stake in shares of Masimo during the fourth quarter worth about $35,000. Smartleaf Asset Management LLC increased its stake in shares of Masimo by 80.0% in the third quarter. Smartleaf Asset Management LLC now owns 306 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 136 shares during the period. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in shares of Masimo in the fourth quarter valued at approximately $44,000. Institutional investors own 85.96% of the company’s stock.

Masimo Stock Performance

Shares of MASI opened at $178.82 on Monday. Masimo Corporation has a one year low of $125.94 and a one year high of $179.00. The company has a market cap of $9.36 billion, a PE ratio of -16.97, a P/E/G ratio of 1.81 and a beta of 1.11. The stock has a 50-day moving average of $178.45 and a 200-day moving average of $159.41. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.68 and a quick ratio of 1.45.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on MASI shares. Stifel Nicolaus set a $180.00 price target on shares of Masimo in a research note on Tuesday, February 17th. Wolfe Research downgraded Masimo from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 19th. Piper Sandler lowered Masimo from an “overweight” rating to a “hold” rating and set a $180.00 target price for the company. in a research report on Tuesday, February 17th. Weiss Ratings raised Masimo from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, May 6th. Finally, BTIG Research lowered Masimo from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 18th. Nine equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Masimo has an average rating of “Hold” and an average target price of $180.40.

Read Our Latest Analysis on MASI

About Masimo

(Free Report)

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.

Further Reading

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Corporation (NASDAQ:MASIFree Report).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.